Real-world studies have suggested similar incidences in NSCLC and melanoma patients, at approximately 5% for anti-PD-1/PD-L1 monotherapy and 10% for combination ipilimumab and nivolumab (Naidoo et al., 2017). Here, PDCD1 is linked to melanoma.